news

The Malaysian International Food & Beverage Trade Fair (MIFB 2026) concluded successfully at the Kuala Lumpur Convention Centre (KLCC) from July 15 to 17, 2026. As an enterprise with 29 years of deep expertise in the field of small-molecule bioactive peptides, Tai Ai Peptide Group once again made a significant appearance at this premier Southeast Asian B2B food and beverage trade platform. Led by Chairperson Ms. Wu Xia, the core team from the International Business Division showcased a comprehensive range of peptide raw materials, functional food solutions, and new products tailored specifically for the Southeast Asian market. Engaging with global clients to explore new opportunities in the health food industry, the Group successfully completed this international business venture.

01. Focusing on the Cutting Edge: Peptide Products Shine on the ASEAN Stage

MIFB 2026 brings together over 600 exhibitors from more than 80 countries and regions and attracts over 20,000 professional buyers, serving as a pivotal hub connecting to the ASEAN consumer market of 690 million people. Guided by the theme “Empowering Health through Technology, Leading the Global Market with Peptides,” Tai Ai Peptide Group has meticulously designed an international-standard booth to showcase core ingredients—such as collagen peptides and plant protein peptides—alongside one-stop ODM/OEM customization services tailored for diverse applications, including food, health supplements, foods for special dietary uses, and beverages.

02. Precise Matching, Yielding Fruitful Cooperation Outcomes

During the exhibition, the Tai Ai Peptide team leveraged professional service and efficient communication to reach intentions for in-depth cooperation with numerous high-quality business partners. Through the organizer’s precision buyer-matching program, the Group established preliminary partnerships with several leading ASEAN food enterprises and cross-border e-commerce platforms. In-depth discussions were held regarding peptide raw material supply, joint product development, and regional brand distributorship, laying a solid foundation for expanding the Group’s presence in the Southeast Asian market.

03. Deepening Engagement with ASEAN, Embarking on a New Journey of Globalization

As the core hub for Tai Ai Peptide Group’s operations in Southeast Asia, Malaysia plays a pivotal role in the Group’s globalization strategy. Since its debut at the MIFB exhibition in 2025, the Group has continuously deepened its presence in the local market. Leveraging 29 years of scientific research expertise, numerous proprietary patents, over 300 research achievements, and an integrated industry chain spanning R&D, production, marketing, and service, the Group delivers safe, efficient, and reliable peptide-based health solutions to the ASEAN market. The successful conclusion of MIFB 2026 marks a significant step forward in the Group’s strategic expansion across Southeast Asia.

Looking ahead, the Group will continue to deepen regional operations with Malaysia as its base, establishing local R&D and production facilities. By collaborating with local partners, the Group aims to foster the deep integration of Chinese peptide biotechnology with the ASEAN health industry, ensuring that peptide products reach end consumers more swiftly and reliably, thereby contributing to the high-quality development of the global health and wellness industry.

Leading the way in peptide health for a shared, prosperous future. Tai Ai Peptide Group remains steadfast in its founding mission—”dedicating a lifetime to perfecting peptides.” Driven by technological innovation and guided by market demand, the Group continues to expand its global partnerships, contributing China’s strength to building a global community of health.

Tai Ai Peptide Group

Founded in 1997, Tai Ai Peptide Group has dedicated 29 years to scientific research in the field of peptides. Recognized as a high-tech enterprise and a registered manufacturer and exporter with Customs, the Group has evolved into a comprehensive enterprise integrating the R&D, production, sales, and service of peptide products. Leveraging robust domestic and international research capabilities, Tai Ai Peptide Group has mastered three core technologies—whole-substance chain extraction, single-substance isolation, and proprietary enzymatic hydrolysis. The Group holds numerous national invention and utility model patents and has collaborated with major domestic universities on clinical trials, resulting in over a hundred scientific research achievements. Focusing on full-industry-chain services for small-molecule peptides, the Group operates three major production bases in Langfang (Hebei), Dalian (Liaoning), and Heze (Shandong). Its diverse business portfolio spans food ingredients, pharmaceutical raw materials, health supplements, and foods for special medical or dietary purposes. The company provides comprehensive global solutions, including raw peptide powder, ODM, OEM, and brand agency services. Its annual production capacity for raw peptide powder exceeds 5,000 tons, with products exported to more than 40 countries and regions worldwide.